NASDAQ:HALO Halozyme Therapeutics (HALO) Stock Price, News & Analysis $56.23 +0.26 (+0.46%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$55.63▼$57.0550-Day Range$42.76▼$55.9752-Week Range$32.83▼$57.08Volume831,949 shsAverage Volume1.25 million shsMarket Capitalization$7.16 billionP/E Ratio23.24Dividend YieldN/APrice Target$58.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Halozyme Therapeutics alerts: Email Address Halozyme Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside3.8% Upside$58.38 Price TargetShort InterestBearish6.92% of Float Sold ShortDividend StrengthN/ASustainability-1.12Upright™ Environmental ScoreNews Sentiment0.76Based on 18 Articles This WeekInsider TradingSelling Shares$2.29 M Sold Last QuarterProj. Earnings Growth24.32%From $3.66 to $4.55 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.81 out of 5 starsMedical Sector39th out of 936 stocksBiological Products, Except Diagnostic Industry2nd out of 154 stocks 2.4 Analyst's Opinion Consensus RatingHalozyme Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageHalozyme Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Halozyme Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.92% of the float of Halozyme Therapeutics has been sold short.Short Interest Ratio / Days to CoverHalozyme Therapeutics has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Halozyme Therapeutics has recently decreased by 3.44%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldHalozyme Therapeutics does not currently pay a dividend.Dividend GrowthHalozyme Therapeutics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHalozyme Therapeutics has received a 65.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Biopharmaceuticals" and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Halozyme Therapeutics is -1.12. Previous Next 3.8 News and Social Media Coverage News SentimentHalozyme Therapeutics has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Halozyme Therapeutics this week, compared to 6 articles on an average week.Search Interest17 people have searched for HALO on MarketBeat in the last 30 days. This is an increase of 6% compared to the previous 30 days.MarketBeat Follows14 people have added Halozyme Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,294,050.00 in company stock.Percentage Held by InsidersOnly 2.40% of the stock of Halozyme Therapeutics is held by insiders.Percentage Held by Institutions97.79% of the stock of Halozyme Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Halozyme Therapeutics' insider trading history. Previous Next 4.4 Earnings and Valuation Earnings GrowthEarnings for Halozyme Therapeutics are expected to grow by 24.32% in the coming year, from $3.66 to $4.55 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Halozyme Therapeutics is 23.24, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.45.Price to Earnings Ratio vs. SectorThe P/E ratio of Halozyme Therapeutics is 23.24, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 164.48.Price to Earnings Growth RatioHalozyme Therapeutics has a PEG Ratio of 0.56. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHalozyme Therapeutics has a P/B Ratio of 89.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Halozyme Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Halozyme Therapeutics Stock (NASDAQ:HALO)Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.Read More HALO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HALO Stock News HeadlinesJuly 26 at 4:50 AM | insidertrades.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Sells $551,200.00 in StockJuly 24 at 5:34 AM | insidertrades.comInsider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) CFO Sells 5,000 Shares of StockJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 30, 2024 | insidertrades.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) CFO Nicole Labrosse Sells 10,000 SharesJuly 25 at 5:06 AM | americanbankingnews.comNicole Labrosse Sells 5,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) StockJuly 24 at 4:55 AM | americanbankingnews.comHalozyme Therapeutics (NASDAQ:HALO) Reaches New 52-Week High on Analyst UpgradeJuly 23 at 8:30 AM | prnewswire.comHalozyme to Report Second Quarter 2024 Financial and Operating ResultsJuly 22, 2024 | americanbankingnews.comHalozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $49.00 at The Goldman Sachs GroupJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 22, 2024 | americanbankingnews.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 18, 2024 | investorplace.com3 Biotech Stocks That Could Be Multibaggers in the Making: July EditionJuly 17, 2024 | 247wallst.comAdd These 5 Hot Biotech Stocks In JulyJuly 17, 2024 | americanbankingnews.comHalozyme Therapeutics (NASDAQ:HALO) Given "Buy" Rating at HC WainwrightJuly 15, 2024 | investorplace.com3 Biotech Stocks to Buy Now: Q3 EditionJuly 5, 2024 | investorplace.com3 Highly Rated Biotech Stocks for Your July Buy ListJuly 3, 2024 | investors.comHow Small Biotech Halozyme, With A 41% Run, Is Getting Under Your SkinJuly 1, 2024 | investorplace.com3 Breakout Biotech Stocks on Track to Double by 2032June 25, 2024 | prnewswire.comHalozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple SclerosisSee More Headlines Receive HALO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Confirmed)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:HALO CUSIP40637H10 CIK1159036 Webwww.halozyme.com Phone858-794-8889Fax858-704-8311Employees373Year Founded1998Price Target and Rating Average Stock Price Target$58.38 High Stock Price Target$71.00 Low Stock Price Target$49.00 Potential Upside/Downside+3.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$2.42 Trailing P/E Ratio23.24 Forward P/E Ratio15.36 P/E Growth0.56Net Income$281.59 million Net Margins36.94% Pretax Margin45.44% Return on Equity225.71% Return on Assets20.52% Debt Debt-to-Equity Ratio8.44 Current Ratio6.64 Quick Ratio5.36 Sales & Book Value Annual Sales$829.25 million Price / Sales8.63 Cash Flow$3.24 per share Price / Cash Flow17.35 Book Value$0.63 per share Price / Book89.25Miscellaneous Outstanding Shares127,270,000Free Float124,219,000Market Cap$7.16 billion OptionableOptionable Beta1.27 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Helen I. Torley M.B. Ch. B. (Age 61)M.R.C.P., President, CEO & Director Comp: $1.82MMs. Nicole LaBrosse (Age 41)Senior VP & CFO Comp: $849.36kDr. Michael J. LaBarre Ph.D. (Age 60)Senior VP & CTO Comp: $843.89kMr. Mark Snyder Esq.Senior VP & Chief Legal OfficerMs. Cortney Caudill M.B.A.Chief Operations OfficerMs. Tram BuiHead of Investor Relations & Corporate CommunicationsMs. Amy Marinne FoxChief Human Resources OfficerMr. Gary GroteChief Commercial OfficerDr. Christopher Wahl M.B.A.M.D., Chief Business OfficerMore ExecutivesKey CompetitorsMomenta PharmaceuticalsNASDAQ:MNTAChina Biologic ProductsNASDAQ:CBPOTwist BioscienceNASDAQ:TWSTIovance BiotherapeuticsNASDAQ:IOVARelay TherapeuticsNASDAQ:RLAYView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCSold 13,280 shares on 7/26/2024Ownership: 0.537%EFG Asset Management North America Corp.Bought 180 shares on 7/26/2024Ownership: 0.110%Shaker Investments LLC OHBought 14,245 shares on 7/26/2024Ownership: 0.053%State of Michigan Retirement SystemSold 1,800 shares on 7/26/2024Ownership: 0.024%Legato Capital Management LLCBought 14,613 shares on 7/26/2024Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions HALO Stock Analysis - Frequently Asked Questions How have HALO shares performed this year? Halozyme Therapeutics' stock was trading at $36.96 at the beginning of the year. Since then, HALO stock has increased by 52.1% and is now trading at $56.23. View the best growth stocks for 2024 here. How were Halozyme Therapeutics' earnings last quarter? Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its quarterly earnings results on Tuesday, May, 7th. The biopharmaceutical company reported $0.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.07. The biopharmaceutical company earned $195.88 million during the quarter, compared to analysts' expectations of $201.72 million. Halozyme Therapeutics had a net margin of 36.94% and a trailing twelve-month return on equity of 225.71%. What is Helen Torley's approval rating as Halozyme Therapeutics' CEO? 12 employees have rated Halozyme Therapeutics Chief Executive Officer Helen Torley on Glassdoor.com. Helen Torley has an approval rating of 75% among the company's employees. Does Halozyme Therapeutics have any subsidiaries? Halozyme Therapeutics subsidiaries include Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH. Who are Halozyme Therapeutics' major shareholders? Top institutional shareholders of Halozyme Therapeutics include Allspring Global Investments Holdings LLC (0.54%), Boston Trust Walden Corp (0.35%), Swedbank AB (0.26%) and Retirement Systems of Alabama (0.25%). Insiders that own company stock include Helen Torley, Michael J Labarre, Matthew L Posard, Jeffrey William Henderson, James M Daly, Nicole Labrosse, Connie Matsui and Jean-Pierre Bizzari. View institutional ownership trends. How do I buy shares of Halozyme Therapeutics? Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Halozyme Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Halozyme Therapeutics investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD) and Athabasca Oil (ATH). This page (NASDAQ:HALO) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.